Quick Answer
Coya Therapeutics, Inc. reported Operating Income Loss of -$22.56 million for the year ending 2025.
- Coya Therapeutics, Inc. showed a decrease of -30.8% in Operating Income Loss from 2024 to 2025.
- This data is from Coya Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$1.70 million | Q2 2022: -$3.45 million | Q3 2022: -$2.66 million | Q1 2023: -$2.90 million | Q2 2023: -$3.25 million | Q3 2023: -$3.56 million | Q1 2024: -$5.48 million | Q2 2024: -$3.24 million | Q3 2024: -$4.45 million | Q1 2025: -$7.68 million | Q2 2025: -$6.41 million | Q3 2025: -$2.43 million.
- Over the full 5 years of available data (2021 to 2025), Coya Therapeutics, Inc.'s Operating Income Loss has declined by 363.1%.
- Historical annual values: Fiscal year 2025: -$22.56 million | Fiscal year 2024: -$17.25 million | Fiscal year 2023: -$7.90 million | Fiscal year 2022: -$9.81 million | Fiscal year 2021: -$4.87 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: